Quantitative structure–pharmacokinetic relationships
暂无分享,去创建一个
Donald E Mager | D. Mager | Chao Xu | Chao Xu
[1] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[2] Jin Sun,et al. Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. , 2009, European journal of medicinal chemistry.
[3] Leo Breiman,et al. Bagging Predictors , 1996, Machine Learning.
[4] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[5] Fahima Nekka,et al. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. , 2010, Journal of pharmaceutical sciences.
[6] Yoshitaka Yano,et al. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. , 2004, Journal of pharmaceutical sciences.
[7] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[8] Kazuya Maeda,et al. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.
[9] M. Thomson,et al. Intestinal Metabolism and Transport of Drugs in Children: The Effects of Age and Disease , 2008, Journal of pediatric gastroenterology and nutrition.
[10] Joseph V. Turner,et al. Bioavailability Prediction Based on Molecular Structure for a Diverse Series of Drugs , 2004, Pharmaceutical Research.
[11] S. Ekins,et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.
[12] Berith F. Jensen,et al. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. , 2007, Journal of medicinal chemistry.
[13] A. Tropsha,et al. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.
[14] Peter E. Hart,et al. Nearest neighbor pattern classification , 1967, IEEE Trans. Inf. Theory.
[15] Gisbert Schneider,et al. Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.
[16] R. Bursi,et al. (Q) SAR study on the metabolic stability of steroidal androgens. , 2001, Journal of molecular graphics & modelling.
[17] Hannah M Jones,et al. SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.
[18] Nikhil S. Ketkar,et al. High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods. , 2008, Journal of medicinal chemistry.
[19] J V Gobburu,et al. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. , 1996, Journal of pharmaceutical sciences.
[20] M. Rowland,et al. Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethylbarbituric acids in the isolated perfused rat kidney preparation. , 1988, Journal of pharmaceutical sciences.
[21] M. Karelson. Molecular descriptors in QSAR/QSPR , 2000 .
[22] B. Kowalski,et al. Partial least-squares regression: a tutorial , 1986 .
[23] David A Winkler,et al. Neural networks as robust tools in drug lead discovery and development , 2004, Molecular biotechnology.
[24] F. Theil,et al. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.
[25] Y. Sugiyama,et al. Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure—Pharmacokinetic relationships , 1988, Journal of Pharmacokinetics and Biopharmaceutics.
[26] Anders Karlén,et al. Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[27] Yojiro Sakiyama,et al. Predicting human liver microsomal stability with machine learning techniques. , 2008, Journal of molecular graphics & modelling.
[28] L. Aarons,et al. Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[29] Tingjun Hou,et al. ADME evaluation in drug discovery , 2002, Journal of molecular modeling.
[30] Hao Sun,et al. Structure‐based Drug Metabolism Predictions for Drug Design , 2010, Chemical biology & drug design.
[31] Ravi Iyengar,et al. Network analyses in systems pharmacology , 2009, Bioinform..
[32] Johannes Grotendorst,et al. Classification of Highly Unbalanced CYP450 Data of Drugs Using Cost Sensitive Machine Learning Techniques , 2007, J. Chem. Inf. Model..
[33] Seung-Hoon Choi,et al. Artificial neural network models for prediction of intestinal permeability of oligopeptides , 2007, BMC Bioinformatics.
[34] M Jamei,et al. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.
[35] Chris de Graaf,et al. Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.
[36] B. Hill,et al. Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model. , 2007, Journal of pharmaceutical sciences.
[37] Franco Lombardo,et al. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.
[38] S Oie,et al. Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.
[39] M Paul Gleeson,et al. In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.
[40] Jing Lu,et al. Development of in silico models for human liver microsomal stability , 2007, J. Comput. Aided Mol. Des..
[41] Tingjun Hou,et al. ADME Evaluation in Drug Discovery, 8. The Prediction of Human Intestinal Absorption by a Support Vector Machine , 2007, J. Chem. Inf. Model..
[42] P. Hinderling,et al. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.
[43] Yan Li,et al. Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. , 2005, Bioorganic & medicinal chemistry letters.
[44] Yoshua Bengio,et al. Pattern Recognition and Neural Networks , 1995 .
[45] G L Amidon,et al. A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.
[46] S. Ekins,et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.
[47] N. Pyszczynski,et al. Integrated QSPR--pharmacodynamic model of genomic effects of several corticosteroids. , 2003, Journal of pharmaceutical sciences.
[48] Han van de Waterbeemd,et al. Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..
[49] Ying Zhang,et al. In Silico Modeling of Nonspecific Binding to Human Liver Microsomes , 2008, Drug Metabolism and Disposition.
[50] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.
[51] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[52] L. Berezhkovskiy,et al. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.
[53] Joseph P Balthasar,et al. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. , 2010, Journal of pharmaceutical sciences.
[54] S. O'Brien,et al. Greater than the sum of its parts: combining models for useful ADMET prediction. , 2005, Journal of medicinal chemistry.
[55] Yojiro Sakiyama. The use of machine learning and nonlinear statistical tools for ADME prediction. , 2009, Expert opinion on drug metabolism & toxicology.
[56] Chunxin Zhang,et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. , 2007, Nanomedicine : nanotechnology, biology, and medicine.
[57] Junmei Wang,et al. Genetic Algorithm-Optimized QSPR Models for Bioavailability, Protein Binding, and Urinary Excretion , 2006, J. Chem. Inf. Model..
[58] K Krishnan,et al. An integrated QSPR–PBPK modelling approach for in vitro–in vivo extrapolation of pharmacokinetics in rats , 2008, SAR and QSAR in environmental research.
[59] Sunwoo Park,et al. Predictions of Hepatic Disposition Properties Using a Mechanistically Realistic, Physiologically Based Model , 2008, Drug Metabolism and Disposition.
[60] Michael Gertz,et al. Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data , 2008, Drug Metabolism and Disposition.
[61] M. Rowland,et al. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.
[62] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[63] Kristina Luthman,et al. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.
[64] Gilles Klopman,et al. ADME evaluation. 2. A computer model for the prediction of intestinal absorption in humans. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[65] Scott Boyer,et al. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models , 2007, J. Comput. Aided Mol. Des..
[66] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[67] L. Aarons,et al. Quantitative Structure–Pharmacokinetics Relationships: II. A Mechanistically Based Model to Evaluate the Relationship Between Tissue Distribution Parameters and Compound Lipophilicity , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[68] Søren Balling Engelsen,et al. Prediction of in vitro metabolic stability of calcitriol analogs by QSAR , 2003, J. Comput. Aided Mol. Des..
[69] E. Gifford,et al. The development and validation of a computational model to predict rat liver microsomal clearance. , 2009, Journal of pharmaceutical sciences.
[70] Shraddha S. Nigavekar,et al. 3H Dendrimer Nanoparticle Organ/Tumor Distribution , 2004, Pharmaceutical Research.
[71] Alexander Tropsha,et al. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. , 2006, Journal of medicinal chemistry.
[72] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[73] W. Jusko,et al. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. , 2002, Journal of pharmaceutical sciences.
[74] Franco Lombardo,et al. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.
[75] S. Ekins,et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[76] Jaina Mistry,et al. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. , 2005, Journal of medicinal chemistry.
[77] Junmei Wang,et al. Structure – ADME relationship : still a long way to go ? , 2008 .
[78] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[79] Richard J. Povinelli,et al. Synergistic Use of Compound Properties and Docking Scores in Neural Network Modeling of CYP2D6 Binding: Predicting Affinity and Conformational Sampling , 2006, J. Chem. Inf. Model..
[80] K. Bischoff,et al. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). , 1970, Cancer chemotherapy reports.
[81] Tingjun Hou,et al. ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..
[82] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[83] Scott L Cockroft,et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[84] Tudor I. Oprea,et al. Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.
[85] Jan M. Kriegl,et al. Computational approaches to predict drug metabolism. , 2009, Expert opinion on drug metabolism & toxicology.
[86] D. K. Arrell,et al. Network Systems Biology for Drug Discovery , 2010, Clinical pharmacology and therapeutics.
[87] S. Ekins,et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.
[88] G. Schneider,et al. A Virtual Screening Filter for Identification of Cytochrome P450 2C9 (CYP2C9) Inhibitors , 2007 .
[89] D L Massart,et al. Classification of drugs in absorption classes using the classification and regression trees (CART) methodology. , 2005, Journal of pharmaceutical and biomedical analysis.
[90] Klaus-Robert Müller,et al. A Probabilistic Approach to Classifying Metabolic Stability , 2008, J. Chem. Inf. Model..
[91] Marjo Yliperttula,et al. Computational prediction of oral drug absorption based on absorption rate constants in humans. , 2006, Journal of medicinal chemistry.
[92] A. Galetin,et al. Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations , 2008, Drug Metabolism and Disposition.
[93] Bernd Beck,et al. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors , 2005, J. Comput. Aided Mol. Des..
[94] Y. Z. Chen,et al. Quantitative Structure-Pharmacokinetic Relationships for drug distribution properties by using general regression neural network. , 2005, Journal of pharmaceutical sciences.
[95] Patrick Poulin,et al. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.
[96] Vladimir N. Vapnik,et al. The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.
[97] Glen E. P. Ropella,et al. Tracing Multiscale Mechanisms of Drug Disposition in Normal and Diseased Livers , 2010, Journal of Pharmacology and Experimental Therapeutics.
[98] Franco Lombardo,et al. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.
[99] Gábor Csányi,et al. Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties , 2007, J. Chem. Inf. Model..
[100] G. Amidon,et al. Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.
[101] Z R Li,et al. Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. , 2006, Journal of molecular graphics & modelling.
[102] Quantitative Structure‐Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol) , 2009, Journal of clinical pharmacology.
[103] Johann Gasteiger,et al. Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..
[104] P Veng-Pedersen,et al. Application of neural networks to pharmacodynamics. , 1993, Journal of pharmaceutical sciences.
[105] Sheila Annie Peters,et al. Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis , 2008, Clinical pharmacokinetics.
[106] M Paul Gleeson,et al. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.
[107] D. Mager,et al. Quantitative structure–property relationships of camptothecins in humans , 2009, Cancer Chemotherapy and Pharmacology.
[108] S. Curry,et al. Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.
[109] Thierry Lavé,et al. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. , 2003, Journal of pharmaceutical sciences.
[110] L. Hall,et al. Molecular connectivity in chemistry and drug research , 1976 .
[111] G. Grass,et al. Effect of diverse datasets on the predictive capability of ADME models in drug discovery , 2001 .
[112] Franco Lombardo,et al. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.
[113] F. Theil,et al. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.
[114] S. Ekins,et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.
[115] Donald E Mager,et al. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. , 2006, Advanced drug delivery reviews.
[116] G. Tucker,et al. A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance , 2010, Clinical pharmacokinetics.
[117] Walter Schmitt,et al. A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.
[118] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[119] P. Sinko,et al. Estimating Human Drug Oral Absorption Kinetics from Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for ka and Fa , 2005, Journal of Pharmacology and Experimental Therapeutics.
[120] M. Bermejo,et al. Validation of a biophysical drug absorption model by the PATQSAR system. , 1999, Journal of pharmaceutical sciences.
[121] Anders Karlén,et al. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. , 2004, Journal of medicinal chemistry.
[122] S. Toon,et al. Structure-pharmacokinetic relationships among the barbiturates in the rat. , 1983, The Journal of pharmacology and experimental therapeutics.